CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kiadis Pharma NV is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kiadis Pharma NV
Paasheuvelweg 25A
Phone: +31 202405250p:+31 202405250 Amsterdam, 1105 BP  Netherlands Fax: +31 202405251f:+31 202405251
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Kiadis Pharma NV is a biopharmaceutical company based in the Netherlands. It focuses on development of therapies for patients with life-threatening diseases. Its programs consist of off-the-shelf and haploidentical donor NK-cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies. Its PM21 particle technology enables ex vivo expansion and activation of cytotoxic NK cells supporting multiple high-dose infusions. Its off-the-shelf NK-cell platform is based on NK cells from unique universal donors and can make NK-cell therapy product available for a broad patient population across a potentially wide range of indications. It develops K-NK003 for the treatment of relapse/refractory acute myeloid leukemia, and K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT. In addition, it has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors. It has offices in the United States and Europe.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202012/31/2020Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Supervisory Board MarkWegter 1/1/2015 1/1/2015
Chief Executive Officer, Member of the Management Board ArthurLahr 51 4/4/2017 4/4/2017
Independent Vice Chairman of the Supervisory Board BerndtModig 1/1/2016 1/1/2016
9 additional Officers and Directors records available in full report.

Business Names
Business Name
0RBP
CytoSen Therapeutics, Inc.
KDS
13 additional Business Names available in full report.

General Information
Number of Employees: 103 (As of 12/31/2020)
Outstanding Shares: 40,308,501 (As of 12/31/2020)
Stock Exchange: AMS
Fax Number: +31 202405251


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023